This means that early cancerous cells should be sensitive to PARP inhibitors. However, unlike fully developed tumors, they are not likely to have acquired many genetic changes and are therefore unlikely to have gained resistance to PARP inhibitors.
原因很简单：刚刚失去正常运作的BRCA1或BRCA2等位基因、并且很快将转变成肿瘤的细胞也是难以经受重组的。这意味着早期的癌细胞应该对PARP抑制剂较为敏感。然而，与晚期肿瘤不同的是，它们不太可能得到许多遗传性改变，因此也不太可能对PARP抑制剂具备抵抗力。